These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Comparison of treatment results of prostatic cancer between radical prostatectomy and radiation therapy]. Kanamaru H, Arai Y, Moroi S, Shirahase T, Isogawa Y, Okuno H, Kihara Y, Kuo JY, Taniguchi T, Takeuchi H. Hinyokika Kiyo; 1994 Sep; 40(9):795-801. PubMed ID: 7801839 [Abstract] [Full Text] [Related]
3. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707 [Abstract] [Full Text] [Related]
9. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V. BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [Abstract] [Full Text] [Related]
12. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. J Urol; 1999 Apr; 161(4):1223-7; discussion 1227-8. PubMed ID: 10081874 [Abstract] [Full Text] [Related]
13. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451 [Abstract] [Full Text] [Related]
14. [Treatment of prostate cancer by radiotherapy]. Akino H, Ohyama N, Mori H, Kanamaru H, Okada K, Yoshida M, Ishii Y, Arai Y. Hinyokika Kiyo; 1997 Jun; 43(6):461-4. PubMed ID: 9250500 [Abstract] [Full Text] [Related]
15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E. Cancer J Sci Am; 1997 Jun; 3(2):78-87. PubMed ID: 9099457 [Abstract] [Full Text] [Related]
16. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. J Urol; 2007 Feb; 177(2):526-29; discussion 529-30. PubMed ID: 17222625 [Abstract] [Full Text] [Related]
19. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer]. Heidenreich A, Ohlmann CH. Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337 [Abstract] [Full Text] [Related]
20. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM. Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544 [Abstract] [Full Text] [Related] Page: [Next] [New Search]